NCT00308607View on ClinicalTrials.gov

Bevacizumab, Dacarbazine and Interferon-Alfa to Treat Metastatic Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

December 31, 2008

Study Completion Date

April 30, 2009

Conditions
Metastatic Melanoma
Interventions
DRUG

Bevacizumab (Avastin)

DRUG

dacarbazine

DRUG

interferon-alfa-2a (Roferon-A)

Trial Locations (3)

FIN-70211

Kuopio University Hospital, Kuopio

FIN-90029

Oulu University Hospital, Oulu

FIN-33521

Tampere University Hospital, Tampere

All Listed Sponsors
lead

University of Turku

OTHER

NCT00308607 - Bevacizumab, Dacarbazine and Interferon-Alfa to Treat Metastatic Melanoma | Biotech Hunter | Biotech Hunter